DrugBiological
ALT-801 clinical trials
Also written ALT-801.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Development codes
- ALT-801
- 10
Studies by the year they started
10 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Altimmune, Inc. (5) · Altor BioScience (5)
Often tested with
Tested in the same studies.
Cisplatin (1) · Granulocyte Colony-Stimulating Factor (1) · Filgrastim (1) · Cytarabine (1) · Fludarabine (1)
Studies
Open first, then newest update. How each study uses ALT-801 is read from its arms, and is right about nine times in ten.
Testing it · 10
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaTerminatedPhase 1/2Altor BioScienceNCT01029873Written as ALT-801
- ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1Altimmune, Inc.NCT05134662Written as ALT-801
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityCompletedPhase 1Altimmune, Inc.NCT04561245Written as ALT-801
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerTerminatedPhase 1/2Altor BioScienceNCT01625260Written as ALT-801
- QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1/2Altor BioScienceNCT01670994Written as ALT-801
- Efficacy and Safety of ALT-801 in the Treatment of ObesityCompletedPhase 2Altimmune, Inc.NCT05295875Written as ALT-801
- ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)CompletedPhase 1Altimmune, Inc.NCT05006885Written as ALT-801
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)CompletedPhase 1Altimmune, Inc.NCT05292911Written as ALT-801
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnPhase 1Altor BioScienceNCT01478074Written as ALT-801
- Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesCompletedPhase 1Altor BioScienceNCT00496860Written as ALT-801
Given in every arm · 1 — ALT-801 is usual care beside what is tested
Codes
What other systems call ALT-801 · ClinicalTrials.gg INT006071
- MeSH (NLM) C572627ALT-801One source ClinicalTrials.gov
- UNII (FDA) QWZ40O5W6KALT-801One source FDA
- NCI Thesaurus C71743IL-2 Recombinant Fusion Protein ALT-801One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572627 | ALT-801 | One source ClinicalTrials.gov |
| UNII (FDA) | QWZ40O5W6K | ALT-801 | One source FDA |
| NCI Thesaurus | C71743 | IL-2 Recombinant Fusion Protein ALT-801 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.